PMID- 31095598
OWN - NLM
STAT- In-Data-Review
LR  - 20190610
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 14
IP  - 5
DP  - 2019
TI  - Intermediate-onset colorectal cancer: A clinical and familial boundary between
      both early and late-onset colorectal cancer.
PG  - e0216472
LID - 10.1371/journal.pone.0216472 [doi]
AB  - Comparative studies of colorectal cancer (CRC) according to the age of onset have
      found differences between early-onset CRC (EOCRC) and late-onset CRC (LOCRC).
      Using this as a starting point, we wished to determine whether intermediate-onset
      CRC (IOCRC) might also be considered as an independent group within CRC. We
      performed a retrospective comparative study of the clinicopathological and
      familial features, as well as of the symptoms and their duration, of a total of
      272 subjects diagnosed with CRC classified into three groups according to the
      age-of-onset (98 EOCRC, 83 IOCRC and 91 LOCRC). The results show that from a
      clinicopathological point of view, IOCRC shared certain features with EOCRC
      (gender, prognosis), and with LOCRC (multiple primary CRCs), whereas it also had 
      characteristics that were specific for IOCRC (mean number of associated polyps). 
      A gradual progression was observed from EOCRC to LOCRC from a greater family
      aggregation to sporadic cases, in parallel with a change of Lynch Syndrome cases 
      to the sporadic microsatellite instability pathway, with the IOCRC being a
      boundary group that is more related to EOCRC. With respect to symptoms, duration 
      and correlation with stages, IOCRC appeared more similar to EOCRC. Clinically,
      IOCRC behaves as a transitional group between EOCRC and LOCRC, with features in
      common with both groups, but also with IOCRC-specific features. Excluding cases
      with familial cancer history, the awareness for EOCRC diagnosis should be
      extended to IOCRC.
FAU - Arriba, Maria
AU  - Arriba M
AUID- ORCID: http://orcid.org/0000-0001-6516-643X
AD  - Department of Clinical Biochemistry, "Gregorio Maranon" University Hospital,
      Madrid, Spain.
FAU - Sanchez, Carmen
AU  - Sanchez C
AD  - Department of Surgery, "12 de Octubre" University Hospital, Madrid, Spain.
FAU - Vivas, Alfredo
AU  - Vivas A
AD  - Department of Surgery, "12 de Octubre" University Hospital, Madrid, Spain.
FAU - Nutu, O A
AU  - Nutu OA
AD  - Department of Surgery, "12 de Octubre" University Hospital, Madrid, Spain.
FAU - Rueda, Daniel
AU  - Rueda D
AD  - Molecular Biology Laboratory, "12 de Octubre" University Hospital, Madrid, Spain.
AD  - Centre for Biomedical Research of "12 de Octubre" University Hospital, Madrid,
      Spain.
FAU - Tapial, Sandra
AU  - Tapial S
AD  - Centre for Biomedical Research of "12 de Octubre" University Hospital, Madrid,
      Spain.
FAU - Rodriguez, Yolanda
AU  - Rodriguez Y
AD  - Department of Pathology, "12 de Octubre" University Hospital, Madrid, Spain.
FAU - Brandariz, Lorena
AU  - Brandariz L
AD  - Department of Surgery, "Fundacion Jimenez Diaz" University Hospital, Madrid,
      Spain.
AD  - Health Research Institute, "Fundacion Jimenez Diaz" University Hospital, Madrid, 
      Spain.
FAU - Garcia, Juan L
AU  - Garcia JL
AD  - Molecular Medicine Unit, Department of Medicine, Institute of Molecular and
      Cellular Biology of Cancer (IBMCC) and Biomedical Research Institute of Salamanca
      (IBSAL), University of Salamanca-SACYL-CSIC, Salamanca, Spain.
FAU - Garcia-Olmo, Damian
AU  - Garcia-Olmo D
AD  - Department of Surgery, "Fundacion Jimenez Diaz" University Hospital, Madrid,
      Spain.
AD  - Health Research Institute, "Fundacion Jimenez Diaz" University Hospital, Madrid, 
      Spain.
FAU - Goel, Ajay
AU  - Goel A
AD  - Center for Gastrointestinal Research, Center for Translational Genomics and
      Oncology, Baylor Scott & White Research Institute, Charles A, Sammons Cancer
      Center, Baylor University Medical Center, Dallas, Texas, United States of
      America.
FAU - Gonzalez-Sarmiento, Rogelio
AU  - Gonzalez-Sarmiento R
AD  - Molecular Medicine Unit, Department of Medicine, Institute of Molecular and
      Cellular Biology of Cancer (IBMCC) and Biomedical Research Institute of Salamanca
      (IBSAL), University of Salamanca-SACYL-CSIC, Salamanca, Spain.
FAU - Urioste, Miguel
AU  - Urioste M
AD  - Centre for Biomedical Network Research on Rare Diseases (CIBERER), Institute of
      Health Carlos III, Madrid, Spain.
AD  - Familial Cancer Clinical Unit, Spanish National Cancer Centre (CNIO), Madrid,
      Spain.
FAU - Perea, Jose
AU  - Perea J
AUID- ORCID: http://orcid.org/0000-0001-5522-8844
AD  - Department of Surgery, "Fundacion Jimenez Diaz" University Hospital, Madrid,
      Spain.
AD  - Health Research Institute, "Fundacion Jimenez Diaz" University Hospital, Madrid, 
      Spain.
LA  - eng
PT  - Journal Article
DEP - 20190516
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
PMC - PMC6521992
COIS- The authors have declared that no competing interests exist.
EDAT- 2019/05/17 06:00
MHDA- 2019/05/17 06:00
CRDT- 2019/05/17 06:00
PHST- 2019/02/17 00:00 [received]
PHST- 2019/04/23 00:00 [accepted]
PHST- 2019/05/17 06:00 [entrez]
PHST- 2019/05/17 06:00 [pubmed]
PHST- 2019/05/17 06:00 [medline]
AID - 10.1371/journal.pone.0216472 [doi]
AID - PONE-D-19-04698 [pii]
PST - epublish
SO  - PLoS One. 2019 May 16;14(5):e0216472. doi: 10.1371/journal.pone.0216472.
      eCollection 2019.